The key trend in analgesics in 2015 was the continuing popularity of faster relief formulations. GlaxoSmithKline New Zealand claimed that its Panadol Rapid brand, which was introduced in the review period, could be absorbed twice as fast as original Panadol and it continued to advertise the brand widely in 2014-2015. It was available in capsules, soluble tablets and a handipack (for on-the-go pain relief). In addition, the company introduced Panadol Extra with Optizorb in 2013. This patented...
Euromonitor International's Analgesics in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2010-2014, allowing you to identify the sectors driving growth. Forecasts to 2019 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Get a detailed picture of the Analgesics market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market’s major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.